ADC Therapeutics SA Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
ADC Therapeutics SA (ADCT) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of -$12.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-08-13
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-06-30 was -$12.00K, a 101.70% decline year-over-year.
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2026-03-31 was -$285.00K, a 186.63% decline year-over-year.
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $185.00K.
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was -$314.00K, a 158.04% decline year-over-year.
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $904.00K.
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$1.33M.
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was -$1.92M, a 153.56% decline from fiscal 2022.
- ADC Therapeutics SA other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was $3.58M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$12.00K 10-Q · filed 2026-08-13 | -$297.00K 10-Q · filed 2026-08-13 | -$112.00K derived: sum of 3 quarters · filed 2026-08-13 | -$426.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$285.00K 10-Q · filed 2026-05-04 | -$100.00K derived: sum of 2 quarters · filed 2026-05-04 | -$414.00K derived: sum of 3 quarters · filed 2026-05-04 | $290.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $185.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$129.00K derived: sum of 2 quarters · filed 2026-03-10 | $575.00K derived: sum of 3 quarters · filed 2026-08-13 | $904.00K 10-K · filed 2026-03-10 |
| 2025-09-30 | -$314.00K 10-Q · filed 2025-11-10 | $390.00K derived: sum of 2 quarters · filed 2026-08-13 | $719.00K 10-Q · filed 2025-11-10 | -$909.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $704.00K 10-Q · filed 2026-08-13 | $1.03M 10-Q · filed 2026-08-13 | -$595.00K derived: sum of 3 quarters · filed 2026-08-13 | -$54.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $329.00K 10-Q · filed 2026-05-04 | -$1.30M derived: sum of 2 quarters · filed 2026-05-04 | -$758.00K derived: sum of 3 quarters · filed 2026-05-04 | -$895.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$1.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.09M derived: sum of 2 quarters · filed 2026-03-10 | -$1.22M derived: sum of 3 quarters · filed 2026-03-10 | -$1.33M 10-K · filed 2026-03-10 |
| 2024-09-30 | $541.00K 10-Q · filed 2025-11-10 | $404.00K derived: sum of 2 quarters · filed 2025-11-10 | $296.00K 10-Q · filed 2025-11-10 | -$896.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | -$137.00K 10-Q · filed 2025-08-12 | -$245.00K 10-Q · filed 2025-08-12 | -$1.44M derived: sum of 3 quarters · filed 2025-08-12 | -$1.69M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$108.00K 10-Q · filed 2025-05-14 | -$1.30M derived: sum of 2 quarters · filed 2025-05-14 | -$1.56M derived: sum of 3 quarters · filed 2025-05-14 | -$1.87M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | -$1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.45M derived: sum of 2 quarters · filed 2025-03-27 | -$1.76M derived: sum of 3 quarters · filed 2025-03-27 | -$1.92M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$256.00K 10-Q · filed 2024-11-07 | -$570.00K derived: sum of 2 quarters · filed 2024-11-07 | -$724.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$314.00K 10-Q · filed 2024-08-06 | -$468.00K 10-Q · filed 2024-08-06 | ||
| 2023-03-31 | -$154.00K 10-Q · filed 2024-05-06 | |||
| 2022-12-31 | $3.58M 10-K · filed 2024-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |